Targeting development of incretin-producing cells increases insulin secretion

Natalia Petersen, Frank Reimann, Johan H. Van Es, Bernard M. Van Den Berg, Chantal Kroone, Ramona Pais, Erik Jansen, Hans Clevers, Fiona M. Gribble, Eelco J.P. De Koning

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

48 Citaten (Scopus)


Glucagon-like peptide-1-based (GLP-1-based) therapies improve glycemic control in patients with type 2 diabetes. While these agents augment insulin secretion, they do not mimic the physiological meal-related rise and fall of GLP-1 concentrations. Here, we tested the hypothesis that increasing the number of intestinal L cells, which produce GLP-1, is an alternative strategy to augment insulin responses and improve glucose tolerance. Blocking the NOTCH signaling pathway with the ã-secretase inhibitor dibenzazepine increased the number of L cells in intestinal organoid-based mouse and human culture systems and augmented glucose-stimulated GLP-1 secretion. In a high-fat diet-fed mouse model of impaired glucose tolerance and type 2 diabetes, dibenzazepine administration increased L cell numbers in the intestine, improved the early insulin response to glucose, and restored glucose tolerance. Dibenzazepine also increased K cell numbers, resulting in increased gastric inhibitory polypeptide (GIP) secretion. Using a GLP-1 receptor antagonist, we determined that the insulinotropic effect of dibenzazepine was mediated through an increase in GLP-1 signaling. Together, our data indicate that modulation of the development of incretin-producing cells in the intestine has potential as a therapeutic strategy to improve glycemic control.

Originele taal-2Engels
Pagina's (van-tot)379-385
Aantal pagina's7
TijdschriftJournal of Clinical Investigation
Nummer van het tijdschrift1
StatusGepubliceerd - 2 jan. 2015
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Targeting development of incretin-producing cells increases insulin secretion'. Samen vormen ze een unieke vingerafdruk.

Citeer dit